Acute myeloid leukemia (AML) is a phenotypically and prognostically heterogeneous
hematopoietic stem cell disease that may be cured in eligible patients with intensive …

Despite therapeutic progress in acute myeloid leukemia (AML), relapse post-allogeneic
hematopoietic stem cell transplantation (allo-HSCT) remains a major challenge. Here, we …

Allogeneic stem cell transplantation (allo-SCT) is a curable method for the treatment of
hematological malignancies. In the past two decades, the establishment of haploidentical …

The treatment of acute myeloid leukemia (AML) has evolved over the past few years with the
advent of next-generation sequencing. Targeted therapies alone or in combination with low …

Despite the curative potential of allogeneic stem cell transplantation (allo-SCT) in patients
with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), many patients …

Introduction Hypomethylating agents (HMAs) seem to have a range of properties favorable
to post-allogeneic hematopoietic stem cell transplantation (allo-SCT) maintenance in acute …

Myelodysplastic syndromes (MDS) are a diverse group of hematological malignancies
distinguished by a combination of dysplasia in the bone marrow, cytopenias and the risk of …

Abstract Dysregulation of DNA (cytosine-5)-methyltransferase 1 (DNMT1) is associated with
the pathogenesis of various types of cancer. It has been previously shown that DNMT1 is …

Simple Summary Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially
curative therapeutic procedure for patients with high risk acute myeloid leukemia. Its anti …

Allo-HSCT remains the standard of care for high-risk AML. Increased access to transplant,
reduced toxicity and relapse are improving patient outcomes. Further research is needed to …